Comparison the anti-tumor effect of pyrotinib, afatinb and T-DM1 in lung cancer organoids and PDX models with HER2 mutation.

e24281Background: Targeted therapy for patients of NSCLC with HER2 mutations is still on unmet need in clinical setting. Pyrotinib, a HER2 and EGFR tyrosine kinase inhibitor, has showed encouraging...